BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18937879)

  • 1. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.
    Ito H; Arakawa R; Takahashi H; Takano H; Okumura M; Otsuka T; Ikoma Y; Shidahara M; Suhara T
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):667-75. PubMed ID: 18937879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
    Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
    Takahata K; Ito H; Takano H; Arakawa R; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Nogami T; Suzuki M; Nagashima T; Shimada H; Kato M; Mimura M; Suhara T
    Psychopharmacology (Berl); 2012 Jul; 222(1):165-72. PubMed ID: 22237854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.
    Muly EC; Votaw JR; Ritchie J; Howell LL
    J Pharmacol Exp Ther; 2012 Apr; 341(1):81-9. PubMed ID: 22214649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
    Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
    J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone.
    Yasuno F; Suhara T; Okubo Y; Sudo Y; Inoue M; Ichimiya T; Tanada S
    Psychopharmacology (Berl); 2001 Feb; 154(1):112-4. PubMed ID: 11292000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride.
    Kim JH; Son YD; Kim HK; Lee SY; Cho SE; Kim YB; Cho ZH
    J Clin Psychopharmacol; 2011 Aug; 31(4):507-11. PubMed ID: 21694619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
    Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
    Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?
    Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Kodaka F; Okumura M; Otsuka T; Suhara T
    J Neurosci; 2009 Oct; 29(43):13730-4. PubMed ID: 19864585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457.
    Ikoma Y; Ito H; Arakawa R; Okumura M; Seki C; Shidahara M; Takahashi H; Kimura Y; Kanno I; Suhara T
    Neuroimage; 2008 Oct; 42(4):1285-94. PubMed ID: 18585466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.